Sponsored by:
General Motors (GM)
General Electric (GE)
Apple (AAPL)
Deere (DE)
Focus Stocks
Featured Stories
S&P Indices Announces Changes to U.S. Indices
Staples, Inc. Announces First Quarter 2012 Performance
Xerox Broke Support
Are the Bears Taking Control over F5 Networks?
Chico's FAS Reports First Quarter Earnings
Forest Laboratories - 52 Week Low
Published on Friday, 18 November 2011 12:34 Written by Christopher Lynn
New York, November 18th (TradersHuddle.com) - Shares of Forest Laboratories, Inc. (NYSE:FRX) booked a new 52 week low by trading below $29.21, traders are definitely monitoring Forest Laboratories' price action to see if this move attracts further selling, or it this last push down sets a tradable bottom in the stock.
Forest Laboratories, Inc. (NYSE:FRX) develops, manufactures, and sells branded and generic forms of ethical drug products. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses.
Forest Laboratories is currently trading -0.1% versus its previous trading session close, and it has calculated support and resistance at $29.77 and $31.77 respectively. Clearly with this action this range has been penetrated, and traders will be reviewing price action to establish a new tradable range
The overall market index S&P 500 is trading lower by -0.29% from its previous trading close, which means that Forest Laboratories stock is outperforming the overall market.
Related Articles
- Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association (APA) Annual Meeting
- New Ratings ( FRX, NEPT, PDCO )
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder
- Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012
- Forest Laboratories, Inc. to Host Investor Meeting to Review Company’s Late-Stage Product Development Pipeline and Commercialization Strategy
- Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per Share of $0.72 Including $0.06 Per Share of Acquisition Amortization
- Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2012 Fourth Quarter Earnings
- Forest Laboratories, Inc. Announces Buyout of Bystolic Royalties from Janssen Pharmaceutica NV
- Forest Laboratories and Almirall Announce FDA has Extended the Review Period for Aclidinium Bromide
- New Surveys Reveal Striking Differences Between Public Perceptions and Private Realities of People With Fibromyalgia
Related Partner Headlines
- Think Like the Father of Value Investing - TheStreet.com
- Notable Call Options Activity in Forest Laboratories - Benzinga
- Forest Laboratories and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients with Major Depressive Disorder - Benzinga
- From Earlier: Forest Laboratories, Inc. and Gedeon Richter Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia - Benzinga
- From Earlier: Forest Laboratories Receives European Marketing Approval for Colobreathe Dry Powder Inhaler - Benzinga
- From Earlier: Forest and Almirall Announce Positive FDA Advisory Committee's Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease - Benzinga
- Analysts' Actions: GOOG, FRX, JBHT, KSU - TheStreet.com
- Forest Labs Posts Weak Quarter - TheStreet.com
Real Money Pro from TheStreet: Headlined by legendary hedge fund manager Doug Kass, our team of market technicians and professional traders hand you unique perspectives and breakthrough investment opportunities.
Access this exciting service -- Real Money Pro -- FREE, right now!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
